A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

Inclusion Criteria:

• Female participants: Agreement to remain abstinent (refrain from heterosexualintercourse) or use contraception as defined by the protocol

• Diagnosis of macular edema associated with non-infectious uveitis (NIU)

• Diagnosis of active or inactive, acute, or chronic NIU of any etiology and of anyanatomical type (anterior, intermediate, posterior, panuveitis)

• BCVA letter score of 73 to 19 letters (inclusive) on Early Treatment DiabeticRetinopathy Study (EDTRS)-like charts

Exclusion Criteria:

• Evidence of active or latent syphilis infection

• Evidence of active or latent tuberculosis infection and/or positive tuberculosisassay, or previous or current HIV diagnosis

• Serious acute or chronic medical or psychiatric illness

• History of major ocular and non-ocular surgical procedures

• Uncontrolled IOP or glaucoma or chronic hypotony

• Any anatomical changes or media opacity in the study eye preventing evaluation ofretina, vitreous, and capture of study images

• Prior use of IVT biologics including anti-VEGFs less than 2-4 months prior to Day 1;received IVT Methotrexate within 4 months prior to Day 1

• Prior macular laser therapy, cataract surgery within 6 months and laser capsulotomywithin 3 months of Day 1

• Topical corticosteroids and/or topical NSAID > 3 drops per day in the 14 days priorto Day 1 (D1); intraocular or periocular corticosteroid injections in the 2 monthsprior to D1; subconjunctival corticosteroid injection within 1 month prior to Day 1;an OZURDEX implant in the 4 months prior to D1; YUTIQ, RETISERT or ILUVIEN implantin the 3 years prior to D1

• Diagnosis of macular edema due to any cause other than NIU

• Any major ocular conditions that may require medical or surgical intervention duringthe study period to prevent vision loss